Clinical Trial Update: A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) [Phase 1]

View source ↗

Summary

The Phase 1 study of MK-8527 in participants with mild and moderate hepatic impairment and in healthy participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• MK-8527

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatic Impairment, Healthy Participants | Phase 1 | Status: COMPLETED